TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Telix disclosed on July 22, 2025, that it had received a subpoena from the SEC "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." Based on this news, Telix ADRs fell by more than 10.4% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance
We recently published . TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the companies that stood stronger last week. TG Therapeutics fell for a third day on Monday, shedding 18 percent to close at $28.72 apiece as investors soured on a lower-than-expected full-year sales guidance. In a statement, TG Therapeutics, Inc. (NASDAQ:TGTX) raised its revenue outlook for Briumvi to a range of $570 million to $575 million from the $560 million previously, but was still lower than the $596 million as expected by analysts. The company also upped its total global revenue target to $585 million for the full year 2025 from its previous outlook of $575 million year-on-year. In the second quarter of the year, TG Therapeutics, Inc. (NASDAQ:TGTX) posted a net income 310-percent expansion in net income to $28.19 million from $6.88 million in the same period last year. Total revenues were also higher by 93 percent to $141 million from $73 million in the same comparable period. The company also swung to a net profit of $33 million from a $3.8-million net loss in the same period last year. While we acknowledge the potential of TGTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14 minutes ago
- Yahoo
Marex Group plc issues statement regarding NINGI Research report
LONDON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ('Marex' or the 'Group'; NASDAQ: MRX), the diversified global financial services platform, provided the following response to the report that was published earlier today by NINGI Research, a short selling fund. Marex rejects this malicious report as a transparent effort to manipulate the share price to enable NINGI to profit from the short position it previously built. The report was published without any involvement by Marex. The report contains factual inaccuracies, misstatements, and misleading allegations. Marex is committed to the highest standards of integrity, managing its business in accordance with regulatory requirements in every jurisdiction where it operates. Marex reports its financial figures in accordance with international reporting standards (IFRS) and adheres to the highest standards of corporate governance. Marex will report its second quarter results on Wednesday August 13, where we look forward to the opportunity to update the market on our recent performance and respond to analyst questions. About Marex:Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to 60 exchanges. The Group provides access to the world's major commodity markets, covering a broad range of clients that include some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 40 offices worldwide, the Group has over 2,400 employees across Europe, Asia and the Americas. For more information visit Enquiries please contact: Marex:Nicola Ratchford / Adam Strachan+44 778 654 8889 / +1 914 200 2508nratchford@ astrachan@ FTI Consulting US / UK+1 919 609 9423 / +44 777 611 1222marex@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
ON Semiconductor (ON) Nosedives 15% as Cautious Market Weighs on Outlook
We recently published . ON Semiconductor Corp. (NASDAQ:ON) is one of the companies that stood stronger last week. ON Semiconductor saw its share prices drop by 15.58 percent on Monday to close at $47.97 apiece as investors soured on its chief executive officer's warning of a cautious market sentiment that could dampen its profits and margins. In an investor call, ON Semiconductor Corp. (NASDAQ:ON) CEO Hassane El-Khoury said that there 'is a lot of uncertainty in the automotive market,' and that both Europe and North America are weak. 'You have the tariff, and you have just the general uncertainty of end market demand. So you see customers waiting to the last minute to place an order and an end,' he was quoted as saying. In the second quarter of the year, ON Semiconductor Corp. (NASDAQ:ON) dropped its attributable net income by 50 percent to $170.3 million from the $338.2 million registered in the same period last year. Revenues decreased by 15 percent to $1.47 billion from $1.73 billion year-on-year. For the third quarter of the year, ON Semiconductor Corp. (NASDAQ:ON) said it expects revenues to end between $1.47 billion and $1.56 billion. While we acknowledge the potential of ON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
